Zhong Ji Longevity Science Group's revenue for the
six
months ended in Dec. 2023 was HK$35.08 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$64.99 Mil.
Zhong Ji Longevity Science Group's Revenue per Share for the
six
months ended in Dec. 2023 was HK$0.02.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.04.
Warning Sign:
Zhong Ji Longevity Science Group Ltd revenue per share has been in decline for the last 5 years.
During the past 13 years, Zhong Ji Longevity Science Group's highest 3-Year average Revenue per Share Growth Rate was 16.60% per year. The lowest was -90.80% per year. And the median was -33.80% per year.
Zhong Ji Longevity Science Group Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zhong Ji Longevity Science Group's Revenue
For the Credit Services subindustry, Zhong Ji Longevity Science Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhong Ji Longevity Science Group's Revenue Distribution in the Credit Services Industry
For the Credit Services industry and Financial Services sector, Zhong Ji Longevity Science Group's Revenue distribution charts can be found below:
* The bar in red indicates where Zhong Ji Longevity Science Group's Revenue falls into.
Zhong Ji Longevity Science Group Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$64.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhong Ji Longevity Science Group (HKSE:00767) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Zhong Ji Longevity Science Group Revenue Related Terms
Thank you for viewing the detailed overview of Zhong Ji Longevity Science Group's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhong Ji Longevity Science Group (HKSE:00767) Business Description
Zhong Ji Longevity Science Group Ltd is an investment holding company engaged in the business of loan facilitation services business, money lending business, securities and investment business, financial and investment advisory and property investment. It is also engaged in research and development and production of longevity biological products, as well as the development of medical service business including cell and gene therapy and detection test. Its segments consist of Loan facilitation services; Money lending; Securities and other investments; Financial and investment advisory; and Property investment. It derives the majority of revenue from Money Lending segment that loan financing for interest income.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:00767 has been successfully added to your 